Favorable Media Coverage Somewhat Unlikely to Affect Brainstorm Cell Therapeutics (BCLI) Stock Price
News stories about Brainstorm Cell Therapeutics (NASDAQ:BCLI) have trended positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Brainstorm Cell Therapeutics earned a news impact score of 0.31 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 47.4176990184396 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- BrainStorm Supports Commitment to ALS Patient Community with Appointment of a Vice President of Patient Advocacy … – PR Newswire (press release) (prnewswire.com)
- BrainStorm Supports Commitment to ALS Patient Community with Appointment of a Vice President of Patient Advocacy and Government Affairs (finance.yahoo.com)
- Brainstorm Cell Therapeutics Inc. (BCLI) noted a price swing of -0.43 … – Stocks Gallery (stocksgallery.com)
- Brainstorm Cell Therapeutics Inc. (BCLI) to Release Earnings on Wednesday (americanbankingnews.com)
Shares of Brainstorm Cell Therapeutics (BCLI) traded down 0.92% during mid-day trading on Tuesday, hitting $4.32. 41,952 shares of the stock traded hands. Brainstorm Cell Therapeutics has a 52 week low of $2.06 and a 52 week high of $5.18. The firm’s 50-day moving average is $4.47 and its 200-day moving average is $4.00. The stock’s market cap is $80.94 million.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings results on Monday, May 15th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.20. On average, analysts forecast that Brainstorm Cell Therapeutics will post ($0.79) earnings per share for the current year.
Several brokerages have recently commented on BCLI. Maxim Group set a $8.00 price objective on shares of Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a research report on Saturday, July 22nd. ValuEngine downgraded shares of Brainstorm Cell Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, July 14th.
TRADEMARK VIOLATION NOTICE: “Favorable Media Coverage Somewhat Unlikely to Affect Brainstorm Cell Therapeutics (BCLI) Stock Price” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/08/08/favorable-media-coverage-somewhat-unlikely-to-affect-brainstorm-cell-therapeutics-bcli-stock-price.html.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.